There are currently 343 clinical trials in Fort Worth, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Cook Children's Medical Center, GSK Investigational Site, Cook Children's Medical Center - Fort Worth and UT Southwestern/Simmons Cancer Center-Fort Worth. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
NCT05633602
Recruiting
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may in... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: Tarrant County Hospital District/JPS Health Network, Fort Worth, Texas
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer
NCT04134260
Recruiting
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechani... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth, Texas
Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Register for Updates
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
NCT04378790
Recruiting
A randomized trial to determine whether simultaneous treatment with spectacles and patching has an equivalent VA outcome compared with sequential treatment, first with spectacles alone followed by patching (if needed), for previously untreated amblyopia in children 3 to <13 years of age.
Gender:
All
Ages:
Between 3 years and 13 years
Trial Updated:
02/05/2024
Locations: Pediatric Eye Specialists, LLP, Fort Worth, Texas
Conditions: Amblyopia
Register for Updates
ADH1 and ADH2 Disease Monitoring Study (DMS)
NCT05227287
Recruiting
A global, multi-center, Disease Monitoring Study (DMS) in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1) or Autosomal Dominant Hypocalcemia Type 2 (ADH2) designed to characterize ADH1 and ADH2 disease presentation and progression through retrospective (past) and longitudinal prospective (over time into the future) data collection.
Gender:
All
Ages:
90 years and below
Trial Updated:
02/05/2024
Locations: The Diabetes & Thyroid Center of Fort Worth (DTC), Fort Worth, Texas
Conditions: Autosomal Dominant Hypocalcemia
Register for Updates
Pompe Disease Registry Protocol
NCT00231400
Recruiting
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes. The objectives of the Registry are: To enhance understanding of the... Read More
Gender:
All
Ages:
All
Trial Updated:
01/31/2024
Locations: Cook Children's Health Care System Site Number : 840024, Fort Worth, Texas
Conditions: Glycogen Storage Disease Type II, Pompe Disease
Register for Updates
A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)
NCT04853576
Recruiting
The purpose of this study is to evaluate the efficacy, safety and tolerability of treatment with EDIT-301 in adult and adolescent participants with severe sickle cell disease (SCD).
Gender:
All
Ages:
Between 12 years and 50 years
Trial Updated:
01/30/2024
Locations: Cook Children's, Fort Worth, Texas
Conditions: Sickle Cell Disease, Hemoglobinopathies
Register for Updates
The Synergy Disc for the Treatment of 2 Level Cervical Degenerative Disc Disease Compared With Cervical Fusion Surgery
NCT05740176
Recruiting
A multicenter, prospective, non-randomized, historically controlled study. To demonstrate the Synergy Disc is at least as safe and effective as conventional anterior cervical discectomy and fusion (ACDF) to treat cervical degenerative disc disease (DDD) in subjects who are symptomatic at two levels from C3 to C7 are and are unresponsive to conservative management. Patients will be evaluated preoperatively, at the time of surgery, and at 6 weeks, and 3, 6, 12, and 24 months after surgery. Follow-... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/15/2024
Locations: DFW Center for Spinal Disorders, Fort Worth, Texas
Conditions: Cervical Degenerative Disc Disease
Register for Updates
Clarifying the Optimal Application of SLT Therapy Trial
NCT04967989
Recruiting
The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/14/2024
Locations: Ophthalmology Associates, Fort Worth, Texas
Conditions: Glaucoma and Ocular Hypertension
Register for Updates
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
NCT04782687
Recruiting
This is a single-arm, phase II, open-label trial to investigate the effects of selinexor (S) in combination with daratumumab, lenalidomide, and dexamethasone (DRd) for first-line treatment of multiple myeloma (MM). FDA has approved selinexor plus dexamethasone in multiple myeloma after four prior therapies, and DRd is also already approved by the FDA for multiple myeloma. This study will use all four (S-DRd) together to treat MM as an initial treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/11/2024
Locations: Texas Oncology, P.A., Fort Worth, Texas
Conditions: Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell, Myeloma-Multiple, Myelomatosis, Plasma Cell Myeloma
Register for Updates
PRECISION Pain Research Registry
NCT04853732
Recruiting
The PRECISION Pain Research Registry enrolls participants with chronic low back pain (cases) and participants who are free of chronic pain (controls) to study the epidemiology and management of chronic pain. The vision of the registry is to conduct research to provide a future for all unbounded by pain.
Gender:
All
Ages:
Between 21 years and 79 years
Trial Updated:
01/11/2024
Locations: University of North Texas Health Science Center, Fort Worth, Texas
Conditions: Chronic Low Back Pain
Register for Updates
Phase 2b Study of ALTO-100 in MDD
NCT05712187
Recruiting
The purpose of this study is to determine efficacy differences between ALTO-100 and placebo, used either as monotherapy or adjunctively to an antidepressant, related to patient characteristics.
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
01/10/2024
Locations: Site 147, Fort Worth, Texas
Conditions: Major Depressive Disorder
Register for Updates
C-Brace Prospective Registry
NCT04640584
Recruiting
To gather prospective safety and effectiveness data for the C-Brace System following the standard of care.
Gender:
All
Ages:
All
Trial Updated:
01/09/2024
Locations: Baker O&P, Fort Worth, Texas
Conditions: Pareses, Lower Extremity
Register for Updates